Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now full pipeline small index

Acromegaly: full-pipeline trial registry

4 of 14 indexed Acromegaly trials are currently recruiting.

Corpus placement: #1,230 of 28,707 conditions by registered trial count.

14 US clinical trials · 4 currently recruiting · #1,230 of 28,707 conditions by registered trial count

Acromegaly: 14 US clinical trials tracked, 4 recruiting.

Acromegaly is the subject of 14 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 5 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Crinetics Pharmaceuticals, running 3 of these trials.

Enrollment posture brief

Registry condition acromegaly

OPEN 4 | RECR 29% | LATE 5 | EARLY 4 | RANK #1230 | SPON 3

Nearest open-share peer: Acne Scars (29% recruiting · 7 trials)

Acute Respiratory Failure35.7%Adherence, Medication35.7%Acromegaly (this)29%Abscess7.1%Adult Nasal Type Extranodal 0%
Open-enrollment share among volume-matched conditions near Acromegaly

Acromegaly lists 4 open slots (29% of 14 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Acromegaly on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Acromegaly is recruiting below its size-band peers.

    4 of 14 indexed trials (28.6%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Acromegaly research.

    Crinetics Pharmaceuticals accounts for 3 of 14 trials (21.4%). 10 distinct sponsors appear on at least one study for this condition label.

  3. Most Acromegaly trials plan to enrol fewer than 100 people.

    Median target enrolment is 72 among the 14 trials that report a genuine target (sentinel values excluded). 10 of those (71.4%) plan for fewer than 100 participants.

  4. Acromegaly research is mostly interventional.

    11 interventional and 3 observational studies make up this index (78.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 23Phase 34Phase 41

Open and recent trials

14 total, page 1 of 1

RECRUITING Phase 3 119 participants

A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs

Debiopharm International

NCT06930625

RECRUITING Phase 2 60 participants

ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly

Alexion Pharmaceuticals

NCT07037420

RECRUITING Phase 1 45 participants

Study of MAR002 in Healthy Men

Marea Therapeutics

NCT07195175

RECRUITING NA 9 participants

Diet in the Management of Acromegaly

Cedars-Sinai Medical Center

NCT05401084

ACTIVE NOT RECRUITING Phase 3 111 participants

A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)

Crinetics Pharmaceuticals

NCT05192382

ACTIVE NOT RECRUITING Phase 3 58 participants

A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly

Crinetics Pharmaceuticals

NCT04837040

ACTIVE NOT RECRUITING Phase 2 43 participants

A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)

Crinetics Pharmaceuticals

NCT04261712

ACTIVE NOT RECRUITING 20 participants

Peri-operative Dynamics of the Growth Hormone Axis in Subjects With Acromegaly

Cedars-Sinai Medical Center

NCT00921609

COMPLETED 520 participants

Treatment Patterns and Treatment Outcomes for Acromegaly

Columbia University

NCT03043586

COMPLETED Phase 4 100 participants

A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly

Pfizer

NCT00068042

COMPLETED 77 participants

Bone MicroArchitecture in Acromegaly

Columbia University

NCT03225040

COMPLETED NA 75 participants

Effects of Growth Hormone Administration on Cardiovascular Risk in Cured Acromegalics With Growth Hormone Deficiency

Massachusetts General Hospital

NCT00182091

COMPLETED Phase 3 72 participants

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly

Camurus AB

NCT04076462

COMPLETED Phase 2 5 participants

Sandostatin LAR Depot vs. Surgery for Treating Acromegaly

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NCT00001860

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 3
Phase 3 4
Phase 4 1

Named interventions

Most-linked intervention names on Acromegaly records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
5 trials
Paltusotine Drug
3 trials
Pegvisomant Drug
2 trials
Sandostatin LAR Drug
1 trials
Sandostatin LAR Depot versus transsphenoidal surgery Drug
1 trials
CAM2029 (octreotide subcutaneous depot) Drug
1 trials
Oral glucose tolerance test Diagnostic test
1 trials
MAR002 Drug
1 trials

US sites by state

Facility locations filed on Acromegaly trials. A trial with sites in several states counts in each.

California 8 trials
Massachusetts 7 trials
Pennsylvania 6 trials
Ohio 5 trials
New York 5 trials
Oregon 4 trials
Texas 3 trials
Nevada 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Acromegaly page

14 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Acromegaly condition card totals 14 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.